Lung fibrosis in COVID-19

COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines.

Recent reports have focused on lung fibrosis.




COVID-19 develops via infection with a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS).

It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic. In subsequent follow-up studies, more than 20% of SARS survivors at one year later had pulmonary fibrosis, indicating that pulmonary fibrosis is a long-term problem [David S. Hui et al., Chest., 2005; Lixin Xie et al., Respir Res., 2005]. In COVID-19 patients, it was reported that fibrosis symptoms were observed in the analysis using CT, and it is speculated that the issue of fibrosis will emerge in the future [Zheng Ye., European Radiology, 2020].


At SMC, we offer an Idiopathic pulmonary fibrosis (IPF) model as a fibrosis model of the lung, with which we have a lots of testing experience.

Since it has been reported that IPF is caused by lung damage due to viral infection, it is speculated that the demand for the development of lung fibrosis therapies will increase after the COVID-19 epidemic subsides.

If you are researching the prevention and treatment of fibrosis by COVID-19, please consider our IPF model.

In addition, we can also offer LPS-induced acute lung injury model for Acute Respiratory Distress Syndrome (ARDS), which can result from the deterioration of COVID-19 pneumonia.


We have a variety of fibrotic and inflammatory disease models as well as the IPF model, and provide drug efficacy evaluation testing services.